Clinical trials: Advanced Esophageal Cancer
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Advanced Esophagus Cancer
Apatinib Treatment for Advanced Esophagus Cancer
Subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.
- Trial name
- NCT03170310
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Trial name
- NCT01474642
- Testing
- Capecitabine/Cisplatin(XP), Capecitabine/Paditaxel(XG)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Samsung Medical Center
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05462873
- Testing
- QEQ278
- Where
- 12 sites in United States, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Stage II Esophageal Cancer, Stage III Esophageal Cancer
A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer
Neoadjuvant chemoradiotherapy(Neo-CRT) plus surgery has been regarded as a standard of care for patients with resectable locally advanced esophageal cancer.
- Trial name
- NCT03708042
- Testing
- Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy
- Volunteers
- 220 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer Stage IIB, Esophageal Cancer Stage III
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer.
- Trial name
- NCT03366883
- Testing
- Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00757549
- Testing
- cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors.
- Trial name
- NCT03386721
- Testing
- simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine
- Where
- 44 sites in United States, Belgium and 13 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The aim of this study is to evaluate the efficacy and safety of the combined treatment with Sacituzumab Tirumotecan in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07128693
- Testing
- Sacituzumab Tirumotecan in combination with tislelizumab, Sacituzumab Tirumotecan in combination with anlotinib
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Although the overall incidence of gastric cancer has steadily declined in many Western countries during the last few decades, it is still one of the most common tumors in China.
- Trial name
- NCT01364493
- Testing
- Trastuzumab+Capecitabine+Oxaliplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking University
Esophageal Cancer
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03736863
- Testing
- Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
- Where
- China
- Volunteers
- 147 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer, Gastric Cancer
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the…
- Conditions
- Esophageal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00537121
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Adenocarcinoma, Gastric Cancer
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, locally advanced or recurrent unresectable disease.
- Trial name
- NCT03959293
- Testing
- Durvalumab, Tremelimumab, FOLFIRI Protocol
- Where
- 35 sites in France
- Volunteers
- 107 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Cancer
Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00701857
- Testing
- cisplatin, Pemetrexed, radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arizona
Esophageal Cancer
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003864
- Testing
- carboplatin, docetaxel
- Where
- 74 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Esophageal Squamous Cell Carcinoma
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
This is a Phase 1, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07203898
- Testing
- IPM514
- Volunteers
- 36 people
- Sponsor
- Beijing Immupeutics Medicine Technology Limited
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, carboplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238147
- Testing
- capecitabine, carboplatin, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Washington